Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jemimah Corpuz

Optometrist Seattle, WA Doctor of Optometry

NPI 1962947978 CMS profile 2792694

3324 Rainier Ave S, Seattle, WA 98144

Open in the dashboard

General payments

$7,514

244 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jemimah Corpuz of Seattle, WA is reported in the CMS Open Payments database as having received $7,514 across 244 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $852 13
2024 General $849 20
2023 General $1,223 48
2022 General $1,506 56
2021 General $1,239 41
2020 General $838 37
2019 General $1,009 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jemimah Corpuz
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Jemimah Corpuz were reported at $852. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Jemimah Corpuz Optometrist median Middle half National median
2019 $1,009 $159 $67–$371 $163
2020 $838 $72 $29–$165 $114
2021 $1,239 $125 $46–$292 $132
2022 $1,506 $162 $66–$374 $149
2023 $1,223 $177 $72–$406 $160
2024 $849 $188 $77–$427 $164
2025 $852 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Mallinckrodt Hospital Products Inc. $1,909 58 payments
  2. Sun Pharmaceutical Industries Inc. $982 34 payments
  3. Johnson & Johnson Vision Care, Inc. $754 50 payments
  4. Bausch & Lomb Americas Inc. $454 10 payments
  5. Mallinckrodt Enterprises LLC $438 16 payments
  6. Oyster Point Pharma, Inc. $398 9 payments
  7. Allergan Inc. $342 11 payments
  8. Eyevance Pharmaceuticals LLC $286 2 payments
  9. Dompe US, Inc. $265 7 payments
  10. Bausch & Lomb, a division of Bausch Health US, LLC $239 14 payments
  11. Other $1,447 33 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,514 244 payments
Products named General payments · program years 2019–2025
  1. ACTHAR Immunology $1,909 58 payments
  2. Cequa $765 29 payments
  3. Acuvue $740 49 payments
  4. ACTHAR Autoimmune And Rare Disease $438 16 payments
  5. INFUSE $356 11 payments
  6. TYRVAYA $343 6 payments
  7. Flarex $286 2 payments
  8. OXERVATE $175 3 payments
  9. VUITY $170 4 payments
  10. LUMIGAN $169 4 payments
  11. Other $2,426 77 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

25

Median for Optometry: 120

Drug cost

$22,681

Median for Optometry: $8,864

Branded share of claims

100%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 14 $12,540
Xiidra Lifitegrast Brand 11 $10,141

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ACTHAR
  • Mallinckrodt Hospital Products Inc. $137
$137 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $125
$125 — —
LUMIGAN
  • AbbVie, Inc. $66
$66 — —
LOTEMAX SM
  • Bausch & Lomb Americas Inc. $50
$50 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $41
$41 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

244 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record